摘要
目的分析脂肪酸合成酶(FAS)在卵巢癌组织中的表达情况及与临床特征的关系。方法选取经过病理检查证实诊断的卵巢组织标本300例,其中150例上皮性卵巢癌(EOC)组织为研究组,50例卵巢交界性肿瘤组织为交界性肿瘤组,50例卵巢良性肿瘤组织为良性肿瘤组,50例正常卵巢组织为对照组。对比4组间FAS的表达情况以及与卵巢癌临床特征的关系。结果研究组的FAS阳性表达率为95.3%,高于另外3组,交界性肿瘤组的FAS阳性表达率为72.0%,高于良性肿瘤组(26.0%)和对照组(14.0%),差异均有统计学意义(P﹤0.05);G3级、Ⅲ+Ⅳ期、有淋巴结转移的EOC组织的FAS光密度值高于G1+G2级、Ⅰ+Ⅱ期、无淋巴结转移的EOC组织,差异均有统计学意义(P﹤0.05)。结论 FAS在卵巢癌的发生、发展以及肿瘤细胞的侵袭和转移中具有重要的作用,卵巢癌患者的FAS表达情况与卵巢癌的淋巴结转移情况、FIGO临床分期以及组织分化程度有着密切的关系。
Objective To analyze the expression of fatty acid synthase（FAS） in ovarian cancer and the relationship with clinical parameters. Method A total of 300 pathologically confirmed ovarian specimens were collected, in which150 cases were with epithelial ovarian cancer（EOC）（study group）, 50 cases were with ovarian borderline tumors（borderline tumor group）, another 50 had benign ovarian tumor（benign tumor group）, and the remaining 50 cases were with normal ovarian tissues（control group）. The expression of FAS among the four groups were compared and the relationship with the clinical parameters of ovarian cancer was investigated. Result The positive rate of FAS expression in the study group was 95.3%, which was significantly higher than that in other three groups. The positive rate of FAS in borderline tumor group was 72.0% and was higher than that in the benign tumor group（26.0%） and in the control group（14.0%）, the differences were statistically significant（P〈0.05）; the optical density of FAS in EOC tissues with grade G3, III＋IV stage disease, and with lymph node metastasis was significantly higher than that with grade G1＋G2, I＋II stage disease, without lymph node metastasis, with statistically significant difference observed（P〈0.05）. Conclusion FAS plays an important role in the occurrence and development of ovarian cancer, as well as in the invasion and metastasis of tumor cells. FAS expression in ovarian cancer patients is closely related to the lymph node metastasis of ovarian cancer, the clinical stage of FIGO and the histological differentiation.
作者
王建瑞
韩滨
李珂
WANG Jianrui;HAN Bin;LI Ke(Department of Pathology, Zhumadian Hospital of Traditional Chinese Medicine, Zhumadian 463000, He＇ nan, Chin)
出处
《癌症进展》
2018年第6期760-762,共3页
Oncology Progress
